A Global Active Surveillance for Community Acquired Pneumonia
NCT00929721
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Adult subjects 50 years of age or older
- Subject must reside in the surveillance area
- Subjects who present to a study healthcare facility where the treating physician clinically suspects CAP
- Any subject who is transferred to a study healthcare facility after already being
hospitalized for 48 hours or more at any other in-patient facility (such as a
community hospital).
- Hospital Acquired pneumonia (ie, develops signs and symptoms of pneumonia after being
hospitalized for 48 hours or more).
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Chrzanow,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Global Active Surveillance for Community Acquired Pneumonia | |||
Official Title ICMJE | Global Active Surveillance for Community-Acquired Pneumonia (CAP) in Adults 50 Years and Older | |||
Brief Summary | This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Not Applicable | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) | |||
Condition ICMJE | Community Acquired Pneumonia | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Subjects with Community-Acquired Pneumonia
Subjects with Community-Acquired Pneumonia Interventions:
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 5172 | |||
Original Estimated Enrollment ICMJE | 30000 | |||
Actual Study Completion Date ICMJE | February 2012 | |||
Actual Primary Completion Date | January 2012 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 50 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Poland | |||
Removed Location Countries | Korea, Republic of | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00929721 | |||
Other Study ID Numbers ICMJE | 6115A1-4000 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |